The Use of Macrolides in Respiratory Diseases
Jeremy Linson, Dekel Stavi, Maor Waldman and Nimrod Maimon
Affiliation: Division of Internal Medicine, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, 84000, Israel.
Keywords: Interstitial lung diseases, macrolides, pulmonary diseases, side effects.
Macrolide are antibiotics active against Gram-positive bacteria, but these agents exhibit also an antiinflammatory
activity with several mechanisms suggested.
The benefit of macrolides in the treatment of pulmonary disease is well known, although in some cases there is a lack of
understanding of the exact pathway in which they contribute to the therapy.
Several studies have examined the benefits of macrolide treatment on patients with chronic asthma. Possible modes of
action include direct anti-bacterial activity, specifically against Chlamydia pneumonia, decreased metabolism of steroid
drugs, and a modulation of the immune response.
Some of the studies show overall asthma symptoms improvement, reducing corticosteroid requirements and an increase in
Cystic Fibrosis patients using macrolide therapy had fewer pulmonary exacerbations, delayed onset of the first pulmonary
exacerbation, and a reduced need for additional antibiotic therapy.
Low dose erythromycin treatment (less than a therapeutic dose for bacterial infection) in patients with diffuse
panbronchiolitis showed significantly survival increase, suggesting that the anti-inflammatory properties of the antibiotic
are responsible for the improvement.
This article will review the use of macrolide therapy in various lung diseases.
Rights & PermissionsPrintExport